A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron (III) salt and an aqueous solution of the oxidation product of one or more maltodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.

A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron (III) salt and an aqueous solution of the oxidation product of one or more maltodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.

Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.

Disclosed herein is a method for alleviating a kidney disease or fibrosis of an organ in a subject, which includes administering to the subject a composition containing a ferrous amino acid chelate which includes ferrous ions and an amino acid.

Disclosed herein is a method for alleviating a kidney disease or fibrosis of an organ in a subject, which includes administering to the subject a composition containing a ferrous amino acid chelate which includes ferrous ions and an amino acid.

Salt formulations, which are resistant to moisture and cooking conditions, are described herein. The formulations provide particles of micronutrients and vitamins encapsulated within heat resistant pH-sensitive water-insoluble polymers, which are packaged within a salt shell. The pH-sensitive, water-insoluble, thermally stable materials stabilize the micronutrients, particularly at high temperatures, such as during food preparation and cooking, and release the micronutrients at the desired locations such as the stomach, small intestine, etc. Preferred pH-sensitive polymers release at a low pH, less than the pH present in the stomach. The particles can be used to deliver daily-recommended doses of micronutrients simultaneously with salt, eliminating the need for vitamin pills. This is particularly important in populations suffering from severe malnutrition.

Salt formulations, which are resistant to moisture and cooking conditions, are described herein. The formulations provide particles of micronutrients and vitamins encapsulated within heat resistant pH-sensitive water-insoluble polymers, which are packaged within a salt shell. The pH-sensitive, water-insoluble, thermally stable materials stabilize the micronutrients, particularly at high temperatures, such as during food preparation and cooking, and release the micronutrients at the desired locations such as the stomach, small intestine, etc. Preferred pH-sensitive polymers release at a low pH, less than the pH present in the stomach. The particles can be used to deliver daily-recommended doses of micronutrients simultaneously with salt, eliminating the need for vitamin pills. This is particularly important in populations suffering from severe malnutrition.

The present invention relates to a composition for use in preventing migration of cancer cells in a subject known or suspected to suffer from cancer, the composition comprising at least one metal complex having the structure (I), formula (I), wherein M is a metal, preferably selected from the group consisting of copper, iron, manganese and zinc, X is X.sup.a or X.sup.b, wherein X.sup.a is selected from the group consisting of O, S and —N(R.sup.1)—, wherein R.sup.1 is H or alkyl, and wherein X.sup.b is a group forming a coordinate covalent bond to a second metal M′, preferably a group O, S or —N(R.sup.1)—, wherein M′ is preferably selected from the group consisting of copper, iron, manganese and zinc, and wherein M′ and M may be the same or different and are preferably the same, Z.sup.1 and Z.sup.2 are independently of each other a, substituted or unsubstituted, -Aryl-O—, -Aryl-N— or heteroaryl group, Y is Y.sup.a or Y.sup.b, wherein Y.sup.a is selected from the group consisting of H, alkyl, —OH, —SH, halogen, and —NR.sup.3R.sup.4, wherein R.sup.3 and R.sup.4, are independently of each other selected from H and alkyl, preferably R.sup.3 and R.sup.4 are both H, and wherein Y.sup.b is a group forming a coordinate covalent bond to M or M′, preferably Y.sup.b is a group O, S or —N(R.sup.Yb1R.sup.Yb2), wherein R.sup.Yb1 and R.sup.Yb1, are, independently of each other, H or alkyl, preferably H, and wherein n and m are integers, which are independently of each other, 0 or 1, Y.sup.2 is water or a halogen, and wherein Y.sup.3 is water or a halogen. The present invention further relates to a combined preparation comprising the aforesaid composition as well as to an in vitro method, for determining whether cancer cells are susceptible to immobilizing by the aforesaid compound.

##STR00001##

The present invention relates to a composition for use in preventing migration of cancer cells in a subject known or suspected to suffer from cancer, the composition comprising at least one metal complex having the structure (I), formula (I), wherein M is a metal, preferably selected from the group consisting of copper, iron, manganese and zinc, X is X.sup.a or X.sup.b, wherein X.sup.a is selected from the group consisting of O, S and —N(R.sup.1)—, wherein R.sup.1 is H or alkyl, and wherein X.sup.b is a group forming a coordinate covalent bond to a second metal M′, preferably a group O, S or —N(R.sup.1)—, wherein M′ is preferably selected from the group consisting of copper, iron, manganese and zinc, and wherein M′ and M may be the same or different and are preferably the same, Z.sup.1 and Z.sup.2 are independently of each other a, substituted or unsubstituted, -Aryl-O—, -Aryl-N— or heteroaryl group, Y is Y.sup.a or Y.sup.b, wherein Y.sup.a is selected from the group consisting of H, alkyl, —OH, —SH, halogen, and —NR.sup.3R.sup.4, wherein R.sup.3 and R.sup.4, are independently of each other selected from H and alkyl, preferably R.sup.3 and R.sup.4 are both H, and wherein Y.sup.b is a group forming a coordinate covalent bond to M or M′, preferably Y.sup.b is a group O, S or —N(R.sup.Yb1R.sup.Yb2), wherein R.sup.Yb1 and R.sup.Yb1, are, independently of each other, H or alkyl, preferably H, and wherein n and m are integers, which are independently of each other, 0 or 1, Y.sup.2 is water or a halogen, and wherein Y.sup.3 is water or a halogen. The present invention further relates to a combined preparation comprising the aforesaid composition as well as to an in vitro method, for determining whether cancer cells are susceptible to immobilizing by the aforesaid compound.

##STR00001##

A solid particulate formulation comprising soluble ferric pyrophosphate and a sachet comprising the solid particulate formulation of soluble ferric pyrophosphate for adding to a dialysis solution are provided. Improved methods of administering soluble ferric pyrophosphate comprising the solid particulate formulations and kits comprising the solid particulate formulation and a dialysis concentrate formulation are also disclosed.